A multicenter, single-arm, prospective clinical study of the clinical efficacy and safety treatment of refractory/relapse of acute myeloid leukemia (AML) with CLAAG-IDA
Latest Information Update: 22 Nov 2017
Price :
$35 *
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Idarubicin (Primary) ; Tretinoin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 06 Sep 2017 New trial record